Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Modified Capecitabine and Oxaliplatin (mCAPOX) for Patients With GI Malignancies

NCT06648785 is registered in ClinicalTrials.gov with University of Vermont Medical Center as lead sponsor.

NCT NCT06648785
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06648785 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Modified Capecitabine and Oxaliplatin (mCAPOX) for Patients With GI Malignancies
Lead sponsor
University of Vermont Medical Center
Phase
Phase 2
Overall status
Enrolling by invitation
Start date
October 21, 2024
Completion date
November 30, 2026
Enrollment
20 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

gi cancers